Tag Archive for: psilocybin

Psychedelic Business News Spotlight - December 24

Psychedelic Business Spotlight – December 24

,
This week in psychedelic business news: FDA green lights a new psilocybin study; MindMed commences LSD treatment for ADHD; Sage Institute shuffles leadership.
FDA Green Lights Tryp Therapeutics' Psilocybin Study on Binge Eating DisorderShutterstock.com

FDA Green Lights Tryp Therapeutics’ Psilocybin Study on Binge Eating Disorder

The pharmaceutical company developing psilocybin-based compounds for diseases with unmet medical needs estimates a $2.9 billion market potential for such a treatment.
A Second Washington City Approves Decriminalizing PsychedelicsShutterstock.com

A Second Washington City Approves Decriminalizing Psychedelics

The psychedelic movement keeps on moving in the Pacific Northwest following Seattle's decriminalization resolution passing earlier this year.
Australia Rejects Bid to Reschedule Psilocybin, MDMA for Therapeutic UseShutterstock.com

Australia Rejects Bid to Reschedule Psilocybin, MDMA for Therapeutic Use

Mind Medicine Australia, a psychedelics advocacy organization that filed the application, says the country "lost a massive opportunity to be a leader in this field with this decision.”
New York Legislator Introduces Bill to Legalize Psilocybin Treatment

New York Legislator Introduces Bill to Legalize Psilocybin Treatment

"Establishing a widespread route to provide New Yorkers with this medical treatment would be a monumental step in providing mental health care to improve lives,” reads the bill.

Compass Pathways Study Finds SSRI Drugs Did Not Impede Psilocybin’s Therapeutic Effect

Chief Medical Officer Guy Goodwin calls study "a strong signal that COMP360 psilocybin therapy could be an adjunctive treatment to SSRI antidepressant as well as a monotherapy."
Microdosing Psilocybin and LSD Rises During Pandemic, Global Drug Survey FindsShutterstock.com

Microdosing LSD and Psilocybin Rises During Pandemic, Global Drug Survey Finds

,
The report also explores how microdosing may impact the use of other prescribed mental health medications.

Psychedelic Business Spotlight: December 3

,
This week in psychedelic business news: MAPS pioneers new funding structure; FDA green lights a Cybin study for Covid-19 distress; Compass Pathways gets new majority stakeholder.
DEA Boosts Psychedelics Production (Again) to Meet Research DemandShutterstock.com

DEA Boosts Psychedelics Production (Again) to Meet Research Demand

Drug Enforcement Agency also addresses concerns from Native American Church regarding peyote poaching for mescaline research.
Compass Pathways Releases Promising New Data from Landmark Psilocybin Therapy TrialShutterstock.com

Compass Pathways Releases Promising New Data from Landmark Psilocybin Therapy Trial

Chief Medical Officer Dr. Guy Goodwin clarifies "COMP360 psilocybin therapy was generally well-tolerated" by patients with treatment-resistant depression, despite some adverse reactions from subjects in the study.